inclusion criteria: individuals with a confirmed covid-19/influenza viral infection, as determined by a qualified laboratory test. a nasal swab or saliva test analyzed by qpcr for covid19 or rapid flu test from nasal swab for influenza. individuals who agree to abstain from sexual intercourse, or agree to use condoms or vaginal diaphragms or other devices designed to prevent contraception, during the entire course of the study exclusion criteria viral infections other than covid-19 or influenza. clinically significant cardiac disease including uncontrolled congestive heart failure and unstable angina pregnancy females of child bearing potential age not on adequate contraception or lactating subjects receiving systemic corticosteroid treatment within one month of screening visit subjects less than 18 years of age hospitalization within last 6 months due to acute exacerbation of airway disease subjects with a clinically significant abnormal chest x-ray within past 12 months medication changes within one month of study entry subjects who have participated in another investigation drug treatment study within the previous month. subjects with a current history of alcohol or recreational drug abuse. subjects who have taken dietary supplements containing pyruvate within 24 hours prior to the screening visit. inclusion of women and minorities every attempt will be made to include all genders, and minorities that present with an active covid-19 or flu infection that are not exempted due to exclusion criteria. -

inclusion criteria: individuals with a confirmed covid-19/influenza viral infection, as determined by a qualified laboratory test. a nasal swab or saliva test analyzed by qpcr for covid19 or rapid flu test from nasal swab for influenza. individuals who agree to abstain from sexual intercourse, or agree to use condoms or vaginal diaphragms or other devices designed to prevent contraception, during the entire course of the study exclusion criteria viral infections other than covid-19 or influenza. clinically significant cardiac disease including uncontrolled congestive heart failure and unstable angina pregnancy females of child bearing potential age not on adequate contraception or lactating subjects receiving systemic corticosteroid treatment within one month of screening visit subjects less than 18 years of age hospitalization within last 6 months due to acute exacerbation of airway disease subjects with a clinically significant abnormal chest x-ray within past 12 months medication changes within one month of study entry subjects who have participated in another investigation drug treatment study within the previous month. subjects with a current history of alcohol or recreational drug abuse. subjects who have taken dietary supplements containing pyruvate within 24 hours prior to the screening visit. inclusion of women and minorities every attempt will be made to include all genders, and minorities that present with an active covid-19 or flu infection that are not exempted due to exclusion criteria. -

inclusion criteria: 1. individuals with a confirmed covid-19/influenza viral infection, as determined by a qualified laboratory test. a nasal swab or saliva test analyzed by qpcr for covid19 or rapid flu test from nasal swab for influenza. 2. individuals who agree to abstain from sexual intercourse, or agree to use condoms or vaginal diaphragms or other devices designed to prevent contraception, during the entire course of the study exclusion criteria 1. viral infections other than covid-19 or influenza. 2. clinically significant cardiac disease including uncontrolled congestive heart failure and unstable angina 3. pregnancy 4. females of child bearing potential age not on adequate contraception or lactating 5. subjects receiving systemic corticosteroid treatment within one month of screening visit 6. subjects less than 18 years of age 7. hospitalization within last 6 months due to acute exacerbation of airway disease 8. subjects with a clinically significant abnormal chest x-ray within past 12 months 9. medication changes within one month of study entry 10. subjects who have participated in another investigation drug treatment study within the previous month. 11. subjects with a current history of alcohol or recreational drug abuse. 12. subjects who have taken dietary supplements containing pyruvate within 24 hours prior to the screening visit. inclusion of women and minorities every attempt will be made to include all genders, and minorities that present with an active covid-19 or flu infection that are not exempted due to exclusion criteria. -

inclusion criteria: 1. individuals with a confirmed covid-19/influenza viral infection, as determined by a qualified laboratory test. a nasal swab or saliva test analyzed by qpcr for covid19 or rapid flu test from nasal swab for influenza. 2. individuals who agree to abstain from sexual intercourse, or agree to use condoms or vaginal diaphragms or other devices designed to prevent contraception, during the entire course of the study exclusion criteria 1. viral infections other than covid-19 or influenza. 2. clinically significant cardiac disease including uncontrolled congestive heart failure and unstable angina 3. pregnancy 4. females of child bearing potential age not on adequate contraception or lactating 5. subjects receiving systemic corticosteroid treatment within one month of screening visit 6. subjects less than 18 years of age 7. hospitalization within last 6 months due to acute exacerbation of airway disease 8. subjects with a clinically significant abnormal chest x-ray within past 12 months 9. medication changes within one month of study entry 10. subjects who have participated in another investigation drug treatment study within the previous month. 11. subjects with a current history of alcohol or recreational drug abuse. 12. subjects who have taken dietary supplements containing pyruvate within 24 hours prior to the screening visit. inclusion of women and minorities every attempt will be made to include all genders, and minorities that present with an active covid-19 or flu infection that are not exempted due to exclusion criteria. -